Search the Newsreel

Organon & Co. (1OGN) Q4 2025 Earnings Report - Results, Call & Slides

Organon & Co. reported Q4 2025 earnings, missing both EPS and revenue expectations with actual EPS of €0.55 against consensus €0.64 and actual revenue of €1.32 billion against an expected €1.35 billion. The company provided a neutral outlook, guiding for roughly flat revenue and …

Cognex Corporation Revenue Breakdown – NASDAQ:CGNX

Alpha Cognition Inc. (ACOG) sees 200,086-share buy by 10% holder

Opaleye Management Inc., a ten percent owner of Alpha Cognition Inc. (ACOG), indirectly purchased a total of 200,086 common shares on July 22–23, 2026. These shares were acquired for Opaleye, L.P. and a separately managed account at weighted average prices of $7.8337 and $7.7953 …

Cognizant (CTSH) Stock Looks Reasonable On Earnings Despite Weak Returns

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cognizant Technology Solutions stock has fallen about 47.1% year to date, yet its valuation checks still lean cheap, which sets up a clear tension between …

Organon & Co. Shareholders Clear Sun Pharma Merger Deal

Organon & Co. shareholders have approved the proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a special virtual meeting. Shareholders also passed a non-binding advisory vote regarding compensation for executive officers in connection with the merger. The final voting results will be …

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD®) and ≥75% improvement in Eczema Area and Severity …

Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8

Organon (NYSE: OGN) announced new data from a post hoc analysis of its Phase 3 ADORING 1 and 2 trials for VTAMA cream, showing early and consistent improvements in atopic dermatitis across pediatric age groups and adults. The cream demonstrated significant skin clearance and …

Cognizant (CTSH) Could Be Near A Growth Turnaround As Q2 Results Loom

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cognizant Technology Solutions is set to report Q2 results that some analysts see as the start of a major turnaround in its growth profile. …

CGNT|Cognyte Software Ltd|Price:8.300|Chg%:+0.110

This article provides a detailed financial overview and analysis of Cognyte Software Ltd (CGNT), an Israel-based company specializing in security and analytics software. It highlights the company's strong fundamentals and high growth potential, despite a forecasted medium-term downward trend in stock price. The analysis …

Cognizant and Gulf Edge Launch Strategic AI & Services Partnership to Accelerate Thailand's AI Transformation

Partnership combines sovereign digital infrastructure, enterprise AI capabilities, and industry expertise to help position Thailand as a leading AI economy in Southeast Asia BANGKOK and TEANECK, N.J., July 23, 2026 /PRNewswire/ -- Cognizant (Nasdaq: CTSH), a leading AI builder and global technology services provider, …

Cognizant and Gulf Edge Announce Strategic Partnership to Accelerate Enterprise AI Adoption in Southeast Asia

Gulf Development Public Company Limited (GULF) Partnership combines Cognizant's global AI engineering capabilities with Gulf Edge's sovereign digital infrastructure to capture the region's growing demand for secure, scalable AI solutions.From left to right: 1. Mr. Thomas Mathew, Vice President, Head of ASEAN and Greater …

Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality

Cognyte Software Ltd. (81M) Q1 2026 Earnings Report - Results, Call & Slides

Cognyte Software Ltd. (81M) has released its Q1 2026 earnings report, showing an actual EPS of €0.06, beating the consensus of <€0.01. The company also reported actual revenue of €83.68M, surpassing the expected €82.29M, with a YoY revenue growth of 15.52%. The next earnings …

Organon (OGN) Names A Canada Chief, Is The Stock Cheap?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Leadership change in Canada puts Organon (OGN) in focus Organon (OGN) is back on investors' radar after Organon Canada appointed Dominic Bégin as President and Managing Director, …

(CGNT) Risk Channels and Responsive Allocation

A quantitative research report on Cognyte Software Ltd. (NASDAQ: CGNT) highlights weak near-term sentiment but identifies an exceptional 67.5:1 risk-reward setup targeting a 17.5% gain with only 0.3% risk. The analysis provides three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored …

Cognition Therapeutics (CGTX) Q2 2024 earnings summary

Cognition Therapeutics (CGTX) announced its Q2 2024 earnings, highlighting progress in its Phase 2 trials for CT-1812 in Alzheimer's, dementia with Lewy bodies (DLB), and dry AMD. The company reported a 39% slowing of cognitive decline in its SHINE Alzheimer's trial and expects topline …

ACOG Options Chain — NASDAQ:ACOG

This article from TradingView provides an overview of the options chain for Alpha Cognition Inc. (ACOG) on the NASDAQ stock market. It highlights features like contract overview, chain volatility, and data for both call and put options, helping users track market movements and assess …

Cognyte names Adam Philpott as chief revenue officer

Cognyte Software Ltd. (NASDAQ:CGNT) has appointed Adam Philpott as Chief Revenue Officer, effective August 1, 2026. Philpott, who brings over 25 years of experience in go-to-market organizations, will report to CEO Elad Sharon and joins the executive management team, succeeding Efi Nuri. This appointment …

Cognizant's Q2 Results Likely to Indicate Start of Major Turnaround in Growth, Wedbush Says

Cognizant Technology Solutions (CTSH) Q2 results are likely to indicate a start of major turnaround PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Cognizant (CTSH) Earnings Expected to Grow: Should You Buy?

Wall Street expects a year-over-year increase in earnings on higher revenues when Cognizant (CTSH) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR

Organon Canada has announced the appointment of Dominic Bégin as its new President and Managing Director. Bégin, a founding member of Organon Canada's leadership team, will focus on expanding the company's presence, driving growth, and increasing patient access to medicines, including biosimilars. He brings …

Cognizant Technology Solutions (CTSH) Projected to Release Quarterly Earnings on Wednesday

Specialized Technology Stocks Q1 Earnings: Cognex (NASDAQ:CGNX) Best of the Bunch

The article analyzes the Q1 earnings of specialized technology stocks, highlighting Cognex (NASDAQ:CGNX) as the top performer with significant revenue and EPS beats. It also discusses PAR Technology's strong quarter and details the weaker performances of OSI Systems and Zebra, alongside Arlo Technologies' results. …

Cognizant Lands Centene Mega Deal Worth Over $500 Mn: Report

Cognizant has reportedly secured a mega deal with Centene, a healthcare company, valued at over $500 million. This significant contract underscores Cognizant's continued presence and success in securing large-scale projects within the healthcare sector.

Cognizant Wins Multi-Year Centene Deal That Could Touch $1 Billion

Cognizant has secured a multi-year technology services deal with US health insurer Centene Corp, reportedly worth between $500 million and $1 billion. This agreement is expected to significantly bolster Cognizant's healthcare business by leveraging its TriZetto platform and new AI frameworks like Agentic AI. …

Cognizant bags over $500 million Centene deal, deepens AI push in healthcare

Cognizant has secured a multi-year technology services contract worth over $500 million, potentially reaching $1 billion, from US health insurer Centene Corp. This deal reinforces Cognizant's position in the healthcare technology market and highlights CEO Ravi Kumar's strategy to expand the company's AI-led healthcare …

Cognizant bags mega deal from Centene, likely worth over $500 million

Cognizant has secured a multi-year technology services deal from US health insurer Centene Corp, reportedly worth over $500 million and potentially up to $1 billion. This deal marks a significant win for Cognizant, especially as Centene had previously restructured a major agreement with them …

Q1 Specialized Technology Earnings: Cognex (NASDAQ:CGNX) Earns Top Marks

FEX, CTSH, ACN, CI: ETF Outflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Large Cap Core AlphaDEX Fund (Symbol: FEX) where we have detected an approximate $270.6 million dollar outflow -- that's a 14.7% decrease …

Organon stock trades steady as women’s health focus meets mixed earnings momentum

Organon stock demonstrates a balance between its specialized women's health portfolio and its recent financial performance. The company, which separated from Merck, reported $6.26 billion in revenue and $586 million in net income for 2023, while managing its debt and maintaining a $0.28 quarterly …

TaskUs Inc - Ordinary Shares Class A (TASK) News, Articles, Events & Latest Updates

This article provides recent news and updates for TaskUs Inc (TASK), including financial results announcements and analyst opinions on its valuation. It highlights the upcoming second-quarter 2026 financial results announcement by TaskUs on August 5, 2026, and features several Zacks articles debating whether TaskUs …

COGNIZANT TECHNOLOGY SOLUTIONS CORP CLASS A - Ro Khanna Congressional Trade on Jun. 02, 2026

This article details a congressional stock trade made by Representative Ro Khanna involving Cognizant Technology Solutions Corp Class A (CTSH) on June 2, 2026. The transaction was a purchase valued between $1,001 and $15,000. Since the trade date, CTSH stock has seen an 18.81% …

COGNIZANT TECHNOLOGY SOLUTIONS CORP SCHEDULE 13G

This article reports on a Schedule 13G filing by Cognizant Technology Solutions Corp (CTSH) on July 17, 2026, indicating a passive stake of 5% or more. The filing is accessible on SEC.gov. It also mentions MLQ.ai, a platform for frontier tech research.

Earn 14% While You Wait To Buy ACN Stock On Sale

Photo by Buffik on Pixabay Here is a way to collect an attractive income stream on a top-tier tech consultant now, which you keep no matter what, while lining up a chance to buy the stock at a serious discount if it keeps falling. …

Alpha Cognition Inc. (ACOG) reports Q1 loss, tops revenue estimates

Alpha Cognition Inc. (ACOG) reported a loss in its first fiscal quarter but exceeded revenue estimates. The company's financial performance showed a mixed outcome with higher-than-expected sales.

[8-K] Organon & Co. Reports Material Event

Organon & Co. has filed an 8-K report providing supplemental disclosures related to its proposed merger with Sun Pharma, which is scheduled for a stockholder vote on July 23, 2026. The disclosures include approximately $700 million in potential synergies, unaudited financial projections through 2030, …